PLK1 and cancer: The detailed SAR studies finally led to the six most potent compounds 29–34 having > tenfold higher inhibitory activity of Plk1 PBD than that of PLHSpT, which offer some potential lead compounds for future drug discovery against Plk1-addicted cancers.